William Blair Weighs in on Aratana Therapeutics Inc’s Q1 2020 Earnings (PETX)

Share on StockTwits

Aratana Therapeutics Inc (NASDAQ:PETX) – Analysts at William Blair issued their Q1 2020 earnings per share (EPS) estimates for Aratana Therapeutics in a research report issued on Wednesday, March 13th. William Blair analyst J. Kreger forecasts that the biopharmaceutical company will earn $0.18 per share for the quarter. William Blair has a “Market Perform” rating and a $4.14 price target on the stock. William Blair also issued estimates for Aratana Therapeutics’ Q2 2020 earnings at $0.05 EPS, Q3 2020 earnings at $0.06 EPS, Q4 2020 earnings at $0.03 EPS and FY2020 earnings at $0.31 EPS.

Aratana Therapeutics (NASDAQ:PETX) last released its earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.06). Aratana Therapeutics had a negative net margin of 41.57% and a negative return on equity of 14.84%. The business had revenue of $4.91 million for the quarter, compared to the consensus estimate of $6.53 million.

Several other equities analysts have also commented on the stock. Zacks Investment Research lowered shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. TheStreet lowered shares of Aratana Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, March 4th. Stifel Nicolaus lowered shares of Aratana Therapeutics from a “buy” rating to a “hold” rating and reduced their target price for the company from $8.00 to $5.00 in a report on Friday, January 11th. Finally, BidaskClub lowered shares of Aratana Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, January 11th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Aratana Therapeutics presently has an average rating of “Hold” and a consensus price target of $6.73.

PETX stock opened at $3.80 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.70 and a current ratio of 3.17. Aratana Therapeutics has a 52 week low of $3.30 and a 52 week high of $7.16. The firm has a market cap of $184.76 million, a P/E ratio of -11.88 and a beta of 1.38.

Several hedge funds have recently added to or reduced their stakes in PETX. BlackRock Inc. grew its holdings in Aratana Therapeutics by 5.5% in the 4th quarter. BlackRock Inc. now owns 3,629,595 shares of the biopharmaceutical company’s stock worth $22,249,000 after acquiring an additional 190,011 shares during the last quarter. Vanguard Group Inc grew its holdings in Aratana Therapeutics by 3.8% in the 3rd quarter. Vanguard Group Inc now owns 2,044,208 shares of the biopharmaceutical company’s stock worth $11,938,000 after acquiring an additional 75,166 shares during the last quarter. Vanguard Group Inc. grew its holdings in Aratana Therapeutics by 3.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,044,208 shares of the biopharmaceutical company’s stock worth $11,938,000 after acquiring an additional 75,166 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Aratana Therapeutics by 0.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,499,167 shares of the biopharmaceutical company’s stock worth $9,190,000 after acquiring an additional 7,971 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Aratana Therapeutics by 10.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,233,219 shares of the biopharmaceutical company’s stock worth $7,559,000 after acquiring an additional 114,383 shares during the last quarter. 68.64% of the stock is currently owned by institutional investors.

In related news, insider Peter Steven St sold 46,094 shares of the stock in a transaction on Monday, December 17th. The shares were sold at an average price of $5.85, for a total transaction of $269,649.90. Following the transaction, the insider now owns 516,626 shares of the company’s stock, valued at approximately $3,022,262.10. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.30% of the stock is currently owned by company insiders.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Read More: What is an Initial Public Offering (IPO)?

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

William Blair Weighs in on Aratana Therapeutics Inc’s Q1 2020 Earnings
William Blair Weighs in on Aratana Therapeutics Inc’s Q1 2020 Earnings
Cadence Bancorp  Stock Rating Upgraded by Zacks Investment Research
Cadence Bancorp Stock Rating Upgraded by Zacks Investment Research
COMPASS GRP PLC/S  Cut to “Sell” at Zacks Investment Research
COMPASS GRP PLC/S Cut to “Sell” at Zacks Investment Research
DXP Enterprises  Stock Rating Upgraded by Zacks Investment Research
DXP Enterprises Stock Rating Upgraded by Zacks Investment Research
Evolent Health  Lowered to “Sell” at Zacks Investment Research
Evolent Health Lowered to “Sell” at Zacks Investment Research
NIO  & The Competition Head-To-Head Survey
NIO & The Competition Head-To-Head Survey


Leave a Reply

© 2006-2019 Ticker Report